Creatio in 2022
At Creatio we are a multidisciplinary team of 24 people with the aim of offering solutions based on advanced therapies to increase the efficiency of the healthcare system.
After a year that still felt the aftermath of the pandemic, 2022 allowed Creatio to catch up again and consolidate the goals that had to be put on hold due to the pandemic. In 2022, the clinical production area consolidated the advances of recent years and achieved important milestones, such as the renewal of ISO certification for another 4 years. On the other hand, the area of basic and translational research obtained 9 new projects (ValCTNED, AlterNED, CT4HD, 4DBR among others)
In terms of training, we have a total of 8 PhD students and 1 industrial PhD in our team. In addition, we have increased the number of followers on social networks and have been able to attend 5 conferences and 1 exhibition.
The results achieved during 2022 are thanks to the effort, dedication, trust and support of the team, clients and collaborators who have believed in our values and mission.
Expertise
Staff
Areas of work
Creatio research team led by Dr. Josep M Canals is focused on the research and translation of Advanced Therapies with a focus on neurodevelopment and neurological diseases under ISO 9001:2015 guidelines. To know more, click here.
avantdrug is dedicated to the validation of new technologies and health products in development by advising and conducting regulatory studies under ISO 9001:2015 and GLP, if requested. To know more, click here.
Creatio develops, validates and manufactures Advanced Therapies Medicinal Products (ATMPs) for clinical research under high quality standards, ISO 9001:2015 and GMP. To know more, click here.
Euros
Private funding projects
Public funding projects
Total publications